Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Update

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw a significant drop in short interest during the month of July. As of July 15th, there was short interest totalling 334,700 shares, a drop of 36.7% from the June 30th total of 529,100 shares. Based on an average daily trading volume, of 124,200 shares, the days-to-cover ratio is presently 2.7 days.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in Oramed Pharmaceuticals in the first quarter worth about $68,000. Murchinson Ltd. raised its holdings in shares of Oramed Pharmaceuticals by 31.4% in the first quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company’s stock worth $4,028,000 after buying an additional 329,495 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter worth approximately $54,000. Finally, BML Capital Management LLC boosted its holdings in Oramed Pharmaceuticals by 61.5% during the 4th quarter. BML Capital Management LLC now owns 1,261,559 shares of the biotechnology company’s stock valued at $2,914,000 after acquiring an additional 480,267 shares during the period. 12.73% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP traded up $0.03 during mid-day trading on Friday, reaching $2.57. The stock had a trading volume of 4,329 shares, compared to its average volume of 148,107. The firm has a market cap of $104.42 million, a price-to-earnings ratio of 9.77 and a beta of 1.79. Oramed Pharmaceuticals has a 12 month low of $1.67 and a 12 month high of $3.67. The business has a fifty day moving average of $2.38 and a 200 day moving average of $2.58.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. On average, research analysts forecast that Oramed Pharmaceuticals will post -0.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, May 20th.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.